ClinicaliQ Trial Snapshot
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — Active Not Recruiting • Phase III • NCT06212999.
- Long-term safety and effectiveness study of povorcitinib for moderate to severe hidradenitis suppurativa in patients completing earlier trials.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]). Conditions: Hidradenitis Suppurativa (HS) Interventions: Povorcitinib Lead Sponsor: Incyte Corporation Planned Enrollment: 617 participants